DCPH Historical PE Ratio image   This DCPH PE ratio history page last updated 11/7/2022
DCPH Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/3/2022
16.43-0.55-2.20NA
Q2 2022
8/4/2022
16.81-0.60-2.40NA
Q1 2022
5/4/2022
10.77-0.80-3.20NA
Q4 2021
2/8/2022
8.16-1.51-6.04NA
Q3 2021
11/2/2021
35.10-1.37-5.48NA
Q2 2021
8/3/2021
29.52-1.21-4.84NA
Q1 2021
5/4/2021
43.29-1.06-4.24NA
Q4 2020
2/9/2021
48.32-1.10-4.40NA
Q3 2020
11/5/2020
64.94-1.13-4.52NA
Q2 2020
8/4/2020
48.53-1.20-4.80NA
Q1 2020
5/5/2020
57.15-1.36-5.44NA
Q4 2019
3/9/2020
47.19-1.31-5.24NA
Q3 2019
11/4/2019
46.00-1.28-5.12NA
Q2 2019
8/2/2019
22.37-0.56-2.24NA
Q1 2019
5/9/2019
24.33-1.25-5.00NA
Q4 2018
3/14/2019
25.50-0.86-3.44NA
Q3 2018
11/8/2018
20.00-0.65-2.60NA
Q2 2018
8/7/2018
36.00-0.65-2.60NA
Q1 2018
5/8/2018
24.67-0.66-2.64NA
Q4 2017
3/28/2018
20.99-0.62-2.48NA
Q3 2017
11/14/2017
17.51-5.85-23.40NA
DCPH PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/3/2022
16.43-0.55-3.46NA
Q2 2022
8/4/2022
16.81-0.60-4.28NA
Q1 2022
5/4/2022
10.77-0.80-4.89NA
Q4 2021
2/8/2022
8.16-1.51-5.15NA
Q3 2021
11/2/2021
35.10-1.37-4.74NA
Q2 2021
8/3/2021
29.52-1.21-4.50NA
Q1 2021
5/4/2021
43.29-1.06-4.49NA
Q4 2020
2/9/2021
48.32-1.10-4.79NA
Q3 2020
11/5/2020
64.94-1.13-5.00NA
Q2 2020
8/4/2020
48.53-1.20-5.15NA
Q1 2020
5/5/2020
57.15-1.36-4.51NA
Q4 2019
3/9/2020
47.19-1.31-4.40NA
Q3 2019
11/4/2019
46.00-1.28-3.95NA
Q2 2019
8/2/2019
22.37-0.56-3.32NA
Q1 2019
5/9/2019
24.33-1.25-3.41NA
Q4 2018
3/14/2019
25.50-0.86-2.82NA
Q3 2018
11/8/2018
20.00-0.65-2.58NA
Q2 2018
8/7/2018
36.00-0.65-7.78NA
Q1 2018
5/8/2018
24.67-0.66NANA
Q4 2017
3/28/2018
20.99-0.62NANA
Q3 2017
11/14/2017
17.51-5.85NANA
Quotes delayed 20 minutes

Email EnvelopeFree DCPH Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Deciphera Pharmaceuticals (DCPH) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

DCTH PE Ratio History
DERM PE Ratio History
DFFN PE Ratio History
DGX PE Ratio History
DHR PE Ratio History
DICE PE Ratio History
DMTK PE Ratio History
DNAY PE Ratio History
DNLI PE Ratio History
DRNA PE Ratio History
How should the DCPH historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Deciphera Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this DCPH Historical PE Ratio page.

What is the average historical PE for DCPH based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The DCPH historical PE ratio using the annualized quarterly earnings method works out to NA.

What is the average historical PE for DCPH based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The DCPH historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the DCPH Historical PE Ratio information for Deciphera Pharmaceuticals' stock. The average DCPH historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average DCPH historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this DCPH historical PE result, against the recent PE: when this page was posted on 11/4/2022, the most recent closing price for DCPH had been 15.91, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on DCPH or any other given stock, valuation analysis for DCPH can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Deciphera Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for DCPH. Thanks for visiting, and the next time you need to research DCPH Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Top Ten Hedge Funds Holding MM, NVLN Insider Buying, Target DMA.

 

DCPH Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.